Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-03-16 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a change in a significant shareholding interest ('Holding in Company') by an entity (First Equity Limited) no longer having a notifiable interest. This type of notification regarding changes in significant share ownership thresholds aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific subject matter is a change in major shareholding, making MRQ the most precise classification over the general RNS fallback.
2020-03-16 English
Grant of Restricted Stock Units and PDMR Dealings
Director's Dealing Classification · 1% confidence The document explicitly details the granting of Restricted Stock Units (RADSUs) to two senior executives (CEO and CFO) of Verona Pharma plc. The notification includes tables titled 'Details of the person discharging managerial responsibilities' and specifies the 'Nature of the transaction' as 'Grant of RADSUs'. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing (DIRS). Although it involves stock awards, the primary purpose and format align with insider transaction reporting rather than a general capital change (SHA) or share repurchase (POS).
2020-03-05 English
Posting of Annual Report and Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is a short announcement (2272 characters) identified by an RNS Number, indicating it is a regulatory filing from the London Stock Exchange's news service. The title explicitly states: 'Posting of Annual Report and Accounts and Notice of AGM'. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document announces that a report (like the Annual Report) 'will be posted to shareholders later today' and directs readers to a website, it is classified as an announcement about the report's publication, not the report itself. This aligns perfectly with the definition of 'Report Publication Announcement' (RPA). While it mentions the AGM, the primary action announced is the posting/release of the Annual Report and the Notice of AGM, making RPA the most accurate fit for this type of release notice.
2020-03-04 English
Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
Earnings Release Classification · 1% confidence The document explicitly states: 'Verona Pharma plc... announces its unaudited results for the full year ended December 31, 2019, and provides a corporate update.' It also mentions financial highlights for the year ended December 31, 2019, and includes operational updates, management changes, and forward-looking statements typical of an annual financial disclosure. Crucially, it concludes with: 'The company today published its audited accounts for the year ended December 31, 2019.' Although it mentions the publication of audited accounts (which might suggest AR or 10-K), the structure, content (full-year results summary, operational review, management changes), and the fact that it is an announcement summarizing the full year strongly points towards the Annual Report category (10-K), which encompasses the full annual financial performance review. Since the text is extensive (175k chars) and contains the detailed results, it is the report itself, not just a publication announcement (RPA). Given the context of a UK-listed company (AIM/Nasdaq) announcing full-year results, 10-K is the closest US equivalent for a comprehensive annual report. FY 2019
2020-02-27 English
Final Results
Earnings Release Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from N4 Pharma PLC titled 'Final Results'. It contains the company's audited financial results for the year ended 31 December 2019, including the Chairman's Report, Consolidated Statement of Comprehensive Income, and Consolidated Statement of Financial Position. While it contains financial data, it is presented as a summary announcement (RNS) rather than the full, standalone Annual Report document. According to the 'Menu vs Meal' rule, this is an announcement of results, which falls under the Earnings Release (ER) category as it provides the initial announcement of yearly financial results with key highlights. FY 2019
2020-02-25 English
Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
Report Publication Announcement Classification · 1% confidence The document text is a press release dated February 21, 2020, from Verona Pharma plc. The core content announces that the company "will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call." This is a forward-looking announcement about the release of financial results and a subsequent conference call, not the results themselves (ER) or the full annual report (10-K). Since it is announcing the upcoming release of financial results and scheduling a call to discuss them, it fits best under the category of announcing the publication of a report, which aligns with Report Publication Announcement (RPA). It is too specific to be a general Regulatory Filing (RNS). The document length is short (3367 chars), supporting the 'announcement' classification over the full report.
2020-02-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.